Search
for
Sort by
Research 61–90 of 336
- Taste disorders and alopecia in myasthenia gravis
- Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double‐blind, placebo‐controlled, phase 1B clinical trial
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Ottawa, Ontario, Canada, February 13–16, 2013
- Frontotemporal dementia with parkinsonism presenting as posterior cortical atrophy
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Abstracts
- Diagnostik und Therapie der kutanen Androgenisierung im klimakterischen Übergang sowie in der Peri- und Postmenopause: Hirsutismus und Alopezie
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
- The Potential Application of Exosomes as Therapeutic Agents, Carriers, and Biomarkers in Skin Diseases
- Hair Oils May Worsen Seborrheic Dermatitis in Black Patients
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Case Report: Bimekizumab for dissecting cellulitis of the scalp
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Extracellular vesicles derived from embryonic day 13 fetal mouse dermal fibroblasts exhibit potential antifibrotic activity
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
- All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
- Comparative Analysis of Plant Exosomes and Human-Derived Exosomes: Structural Differences and Emerging Applications
- Exosomes in Skin Rejuvenation: Systematic Review of Anti-Aging Effects and Clinical Applications
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact